Goodrx Holdings Inc. Stock News

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic

Here is how GoodRx Holdings, Inc. (GDRX) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., today announced it will r

GoodRx Holdings Inc (NASDAQ:GDRX) stock is up 1.9% to trade at $6.87 this morning, after Keybanc upgraded the digital healthcare service to "overweight" from "sector weight," while setting a price ta

Investors interested in Medical Services stocks are likely familiar with Elevance Health (ELV) and GoodRx Holdings, Inc. (GDRX). But which of these two stocks presents investors with the better value

GoodRx got an upgrade from Wells Fargo. The analysts appreciate the company's increased-revenue visibility.

Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or GoodRx Holdings, Inc. (GDRX). But which of these two stocks presents investors with t

The consensus price target hints at a 29.1% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn

Investors interested in stocks from the Medical Services sector have probably already heard of Elevance Health (ELV) and GoodRx Holdings, Inc. (GDRX). But which of these two stocks is more attractive

GoodRx Holdings, Inc. (GDRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Does GoodRx Holdings, Inc. (GDRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key

GoodRx beat Q4 estimates and announced a new $450 million stock repurchase program. The prescription savings specialist also issued better-than-expected 2024 revenue guidance.

Shares of GoodRx Holdings (GDRX) are jumping Thursday as the company posted its fourth quarter earnings, revealing revenue increased by 7% to $196.6 million. The company also issued full-year guidance

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago.